News

Theradiag snaps up Prestizia
Enlarge image

BusinessFrance

Theradiag snaps up Prestizia

28.06.2012 - French theranostics and in vitro diagnostics company Theradiag is set to acquire its compatriot Prestizia, a specialist for microRNA-based diagnostics.

Paris/Marne la Vallee – Prestizia SAS is part of the Holding Incubatrice Biotechnology and Pharmacy, which was launched by Truffle Capital in 2010 and is presided by Jean-Jacques Bertrand, former CEO of Aventis-Pasteur. The company, which has been set up in April 2011 with a starting capital of €300,000, aims at developing novel diagnostic assays for viral infections and human malignancies based on microRNA expression and holds an exclusive license to a technology for characterising HIV cell tropism based on the identification of microRNA signatures.

“The acquisition of Prestizia represents a major advance for Theradiag. Its microRNA platform is going to allow us to strengthen our development in theranostics with a highly innovative, patented technology,” stated Michel Finance, CEO of Theradiag. The Marne la Vallee-based company changed its name from Biomedical Diagnostics (BMD) only last month, to reflect its drive to develop theranostic assays for monitoring the effects of biotherapeutics.

Theradiag pins primary hopes on the newly acquired microRNA technology, stating that it could have widespread clinical applications including identifying patients eligible for particular anti-HIV treatments or for differentiating different cancer types. The first application of this platform is already being developed, in collaboration with the Institut de Génétique Moléculaire de Montpellier (IGMM) for finalising a molecular biology test of HIV tropism to be marketed in the near future.

http://www.european-biotechnology-news.com/news/news/2012-02/theradiag-snaps-up-prestizia.html

Stock MarketsFranceEU

27.03.2015 Europe is once more proving that it can be a good bet for biotech companies going public. A newly established EU-wide lobbying initiative could help the IPO boom on its way.

FinancingPoland

24.03.2015 Poland has announced the closing of a new venture capital fund at US$42m (€32m). The fund, which is the first of its kind in Poland, is dedicated to the Life Sciences with a strong connection to Central and Eastern Europe.

BioeconomyFranceSwedenGermanyNetherlandsFinland

23.03.2015 A BASF-led consortium aims to decrease bio-based production costs using industrial biotechnology. The Horizon2020 funded consortium is the sixth project of the SPIRE Public Private Partnership and has a budget of €14m.

Stock MarketsFranceSwedenUKNorwayIreland

20.03.2015 There are no signs of inertia creeping into the European biotech industry this spring. A total of eight IPOs are set to go public by the end of the year’s first quarter.

FinancingUKEU

17.03.2015 Pharma giants GlaxoSmithKline (GSK) and Johnson & Johnson (J&J) will be key collaborators in a new global fund for dementia research to address the rising threat posed by dementia and Alzheimer’s disease.

FinancingFranceDenmarkSwedenGermany

19.03.2015 French venture capital firm Seventure Partners has raised a further €25m for its microbiome-focused Health for Life Capital Fund. It now stands at €100m.

EventsFranceEUSwitzerlandUKGermany

12.03.2015 With around 1,400 companies and 2,400 participants, the springtime counterpart of BIO-Europe enjoyed a successful premiere in France this year. The overall mood of the European biotech industry was positive, and the French hosts in particular reported new initiatives.

M&ABelgium

11.03.2015 Belgian cell-based therapeutics developer and CMO MaSTherCell SA has been acquired by US biotech Orgenesis Inc. for €23m.

FinancingGermany

10.03.2015 The Gates Foundation has dipped into its purse to bring infectious diseases vaccines to the poorest countries. German vaccine specialist CureVac is set to receive US$52m for their mRNA platform technology.

Stock MarketsIrelandUK

05.03.2015 The IPO wave in the biotech sector shows no signs of slowing down. An Irish life sciences fund set up by former Elan executives plans to raise €325m with its IPO, whilst Summit Therapeutics has announced its IPO pricing of US$34m on Nasdaq.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MEDIGENE12.51 EUR18.92%
  • CO.DON2.88 EUR9.09%
  • FORMYCON26.77 EUR8.91%

FLOP

  • 4SC1.16 EUR-7.20%
  • MOLOGEN5.69 EUR-2.07%
  • CYTOS1.43 CHF-1.38%

TOP

  • CYTOS1.43 CHF320.6%
  • MEDIGENE12.51 EUR194.4%
  • FORMYCON26.77 EUR60.3%

FLOP

  • MORPHOSYS60.10 EUR-19.6%
  • BASILEA108.20 CHF-11.5%
  • WILEX3.10 EUR-9.6%

TOP

  • SANTHERA96.50 CHF2312.5%
  • FORMYCON26.77 EUR271.8%
  • WILEX3.10 EUR198.1%

FLOP

  • CYTOS1.43 CHF-52.5%
  • MOLOGEN5.69 EUR-49.4%
  • PAION2.53 EUR-24.0%

No liability assumed, Date: 30.03.2015